Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Other Operating Expenses (2021 - 2025)

Palisade Bio (PALI) has disclosed Other Operating Expenses for 11 consecutive years, with -$1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 89.94% to -$1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.5 million, a 150.65% increase, with the full-year FY2024 number at -$5.5 million, up 6.26% from a year prior.
  • Other Operating Expenses was -$1.5 million for Q3 2025 at Palisade Bio, down from -$1.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $30.1 million in Q2 2021 to a low of -$27.1 million in Q4 2022.
  • A 5-year average of -$441818.2 and a median of -$1.3 million in 2025 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 7657.29% in 2021, then grew 2.11% in 2025.
  • Palisade Bio's Other Operating Expenses stood at $30.1 million in 2021, then crashed by 190.09% to -$27.1 million in 2022, then soared by 104.55% to $1.2 million in 2023, then soared by 911.35% to $12.5 million in 2024, then crashed by 112.17% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Other Operating Expenses are -$1.5 million (Q3 2025), -$1.1 million (Q2 2025), and -$1.3 million (Q1 2025).